TREATMENT OF CONGENITAL TOXOPLASMOSIS IN NEWBORN INFANTS: AN INTEGRATIVE REVIEW
DOI:
https://doi.org/10.36557/2674-8169.2025v7n7p55-69Keywords:
Toxoplasmosis; Congenital toxoplasmosis; Gestational toxoplasmosis; Fetal toxoplasmosis.Abstract
Introduction: Gestational toxoplasmosis is a zoonosis resulting from infection by the intracellular protozoan Toxoplasma gondii (T. gondii) during pregnancy. This infection can cause potential harm to the fetus, including neurological and ophthalmological manifestations, becoming a significant concern for maternal and child health. The treatment of newborns of mothers with toxoplasmosis is a critical measure, being essentially based on meticulous care and administration of specific drugs, which can reduce the severity of the consequences and the frequency of its late occurrences. Objective: To evaluate the treatment of congenital toxoplasmosis after birth and comment on the possible reduction of the risks of neurological, ophthalmological or auditory sequelae in children with congenital toxoplasmosis infection. Methodology: This is an integrative health research where a review analysis flowchart was used through a specific methodological approach. Thus, 86 articles were found in PubMed, 120 in CAPES and 01 in Revista Pediatica, totaling 207. After applying the exclusion criteria, only 07 remained. Results/Discussion: The gold standard drugs, such as Pyrimethamine, Sulfadiazine, Leucovorin and Spiramycin, play specific roles in the management of the infection. Conclusion: The multifaceted approach and the continuous search for therapeutic improvements are essential to optimize clinical outcomes in the management of newborns.
Downloads
References
ANDRADE, GMQ et al. Toxoplasmose congênita – orientação prática sobre prevenção e tratamento. Rev Med Minas Gerais. 2004;14(1):S85-S91.
ANDRADE, JV et al. Recém-nascidos com risco de toxoplasmose congênita, revisão de 16 anos. Scientia Medica. 2018;28(4):5. Disponível em: https://dialnet.unirioja.es/servlet/articulo?codigo=6999968. Acesso: 04/03/2024
BOBIĆ, B; VILLENA, I,; STILLWAGGON, E. Prevention and mitigation of congenital toxoplasmosis: Economic costs and benefits in diverse settings. Food and waterborne parasitology. 2019;16:e00058.
BOLLANI, L et al. Congenital toxoplasmosis: the state of the art. Frontiers in Pediatrics. 2022;10:894573. Disponível em: https://www.frontiersin.org/articles/10.3389/fped.2022.894573/full. Acesso: 03/03/2024.
COSTA, BSR; PONTES, LN; AMORIM, MVP; GOMES, APB; VERISSIMO, LM. Stability of extemporaneous sulfadiazine oral suspensions from commercially available tablets for treatment of congenital toxoplasmosis. Tropical Medicine & International Health. 2020;25(3):364-372. Disponível em: https://onlinelibrary.wiley.com/doi/full/10.1111/tmi.13354. Acesso: 07/03/2024.
HAJJ RE, TAWK L, ITANI S, HAMIE M, EZZEDDINE J, EL SABBAN M, EL HAJJ H. Toxoplasmosis: Current and emerging parasite druggable targets. Microorganisms. 2021;9(12):2531. Disponível em: https://www.mdpi.com/2076-2607/9/12/2531. Acesso: 07/03/2024.
MCLEOD, R; LYKINS, J; GWENDOLYN, NOBLE A; RABIAH, P; SWISHER, CN; HEYDEMANN, PT; BOYER, K. Management of congenital toxoplasmosis. Current Pediatrics Reports. 2014;2:166-194. Disponível em: https://link.springer.com/article/10.1007/s40124-014-0055-7. Acesso: 08/03/2024.
MURATA, Y et al. Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites. PLoS One. 2017;12(6):e0178203.
PETERSEN, E et al. Congenital toxoplasmosis: Should we still care about screening? Food and Waterborne Parasitology. 2022;27:e00162. Disponível em: https://www.sciencedirect.com/science/article/pii/S2405676622000191. Acesso: 03/03/2024.
RAJAPAKSE S, CHRISHAN SHIVANTHAN M, SAMARANAYAKE N, RODRIGO C, DEEPIKA FERNANDO S. Antibióticos para toxoplasmose humana: uma revisão sistemática de ensaios randomizados. Patog. Glob Saúde. 2013;107:162–169. DOI: 10.1179/2047773213Y.0000000094.
SANTOS DA, SOUZA HFS, SILBER AM, SOUZA TDACBD, Ávila AR. Protein kinases on carbon metabolism: potential targets for alternative chemotherapies against toxoplasmosis. Frontiers in Cellular and Infection Microbiology. 2023;13:1175409. Disponível em: https://www.frontiersin.org/articles/10.3389/fcimb.2023.1175409/full. Acesso: 12/03/2024.
SILVA, MD; TEIXEIRA, C; GOMES, P,; BORGES M. Promising drug targets and compounds with anti-Toxoplasma gondii activity. Microorganisms. 2021;9(9):1960. Disponível em: https://www.mdpi.com/2076-2607/9/9/1960. Acesso: 05/03/2024.
SOUZA, MT; SILVA, MD; CARVALHO, R. Revisão integrativa: o que é e como fazer. Einstein (São Paulo). 2010;8:102-106. Disponível em: https://doi.org/10.1590/S1679-45082010RW1134. Acesso: 28/02/2024
TABILE, PM et al. Toxoplasmose gestacional: uma revisão da literatura. Revista de Epidemiologia e Controle de Infecção. 2015;5(3):158-162. Disponível em: https://www.redalyc.org/pdf/5704/570463811008.pdf. Acesso: 04/03/2024
WOLF, A; COWEN, D;, PAIGE B. Human toxoplasmosis: occurrence in infants as an encephalomyelitis verification by transmission to animals. Science. 1939;89:226-227.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Bianca Claros de Oliveira Fernandes Coêlho
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are copyright holders under a CCBY 4.0 license.
